Search

everythinglearnresearchcommunity

for

Search:↓

A 30-year-old male experienced significant hair regrowth after five months of using topical minoxidil (5% foam) and oral dutasteride (0.5 mg daily). The user reported no side effects and was grateful for the progress, despite the rapid gains slowing down.

A user is treating hair loss with 0.5mg Dutasteride three times a week, 5mg oral Minoxidil daily, and topical finasteride and minoxidil, seeing some improvement but insufficient density. They are considering increasing Dutasteride dosage and addressing high estradiol levels, while also trying to quit vaping.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.

People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.

A user's progress with finasteride and dermarolling to regrow their hairline, with other users noting the improvement.

The conversation suggests considering switching from finasteride to dutasteride for hair loss, with one person stating dutasteride is superior and another advising to wait at least 6 months before making a change. A third person asks for more details, implying it might be too soon to switch.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

Finasteride is preferred for its shorter half-life and FDA approval, while dutasteride is seen as more effective but not FDA-approved for hair loss. Many combine these with minoxidil for improved results, though side effects and effectiveness vary.